Lung disease therapy developer Airway Therapeutics, a Cincinnati Children's Hospital spinoff, has now raised more than $22m in total.
Airway Therapeutics, a US-based lung disease therapy developer spun out from healthcare provider Cincinnati Children’s Hospital Medical Center, has attracted $11m in series B financing from undisclosed new and existing investors.
Airway is developing lung disease therapies from proteins created through recombinant DNA technology, a process where artificial genetic sequences are forged from multiple DNA molecules pulled from differing sources.
The company’s lead product, AT-100, is being developed to treat a chronic breathing disorder mainly afflicting premature-born infants called bronchopulmonary…
